Loading...
OTCM
AVXT
Market cap6kUSD
Nov 03, Last price  
0.00USD
Name

AVAX Technologies Inc

Chart & Performance

D1W1MN
OTCM:AVXT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
617k
-15.98%
100,000100,000100,0001,500,0000541,355770,743930,7271,691,0631,623,701734,774617,384
Net income
-6m
L+19.76%
-1,500,000-4,300,000-5,800,000-7,900,000-16,276,749-15,109,753-9,425,564-3,286,100-3,457,908-3,703,768-5,355,500-6,413,648
CFO
-5m
L+15.59%
-1,300,000-4,000,000-5,100,000-8,100,000-10,371,066-10,844,973-8,972,171-3,696,931-2,578,099-3,710,412-4,093,847-4,731,897

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a potential treatment for non-small cell lung cancer. Established in 1990, the Philadelphia, Pennsylvania-based entity initially operated as Walden Laboratories, Inc. before adopting its current name, AVAX Technologies, Inc., in March 1996.
URL
http://www.avax-tech.com/
IPO date
Dec 19, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show